Which has stronger earnings and valuation, ANVS or ALXO?

ALX Oncology is trading at a lower price-to-earnings ratio than Annovis Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Annovis Bio N/A N/A -$28.85M -$1.79 N/A ALX Oncology N/A N/A -$101.69M -$1.13 N/A

Is ANVS or ALXO more profitable?

ALX Oncology's return on equity of -90.30% beat Annovis Bio's return on equity. Company Net Margins Return on Equity Return on Assets Annovis Bio N/A -685.98% -258.77% ALX Oncology N/A -90.30% -67.28%

Does the media prefer ANVS or ALXO?

In the previous week, ALX Oncology had 1 more articles in the media than Annovis Bio. MarketBeat recorded 3 mentions for ALX Oncology and 2 mentions for Annovis Bio. ALX Oncology's average media sentiment score of 1.27 beat Annovis Bio's score of -0.30 indicating that ALX Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Annovis Bio 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ALX Oncology 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ANVS or FATE?

In the previous week, Fate Therapeutics had 2 more articles in the media than Annovis Bio. MarketBeat recorded 4 mentions for Fate Therapeutics and 2 mentions for Annovis Bio. Fate Therapeutics' average media sentiment score of 0.94 beat Annovis Bio's score of -0.30 indicating that Fate Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Annovis Bio 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Fate Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ANVS or PYXS more profitable?

Pyxis Oncology's return on equity of -215.23% beat Annovis Bio's return on equity. Company Net Margins Return on Equity Return on Assets Annovis Bio N/A -685.98% -258.77% Pyxis Oncology N/A -215.23% -112.19%

Does the media prefer ANVS or PYXS?

In the previous week, Pyxis Oncology had 22 more articles in the media than Annovis Bio. MarketBeat recorded 24 mentions for Pyxis Oncology and 2 mentions for Annovis Bio. Pyxis Oncology's average media sentiment score of 0.60 beat Annovis Bio's score of -0.30 indicating that Pyxis Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Annovis Bio 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Pyxis Oncology 7 Very Positive mention(s) 2 Positive mention(s) 11 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to RNAC or ANVS?

In the previous week, Cartesian Therapeutics and Cartesian Therapeutics both had 2 articles in the media. Cartesian Therapeutics' average media sentiment score of 0.93 beat Annovis Bio's score of -0.30 indicating that Cartesian Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cartesian Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Annovis Bio 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Annovis Bio (ANVS) Competitors

$1.12 -0.07 (-5.46%)

Closing price 09/11/2026 03:58 PM Eastern

Extended Trading

$1.14 +0.01 (+0.89%)

As of 09/11/2026 07:43 PM Eastern

Compare

ANVS vs. ALXO, FATE, ANIK, PYXS, and RNAC

Should you buy Annovis Bio stock or one of its competitors? Annovis Bio's main competitors and comparable companies include ALX Oncology (ALXO), Fate Therapeutics (FATE), Anika Therapeutics (ANIK), Pyxis Oncology (PYXS), and Cartesian Therapeutics (RNAC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Annovis Bio compare to ALX Oncology?

Annovis Bio (NYSE:ANVS) and ALX Oncology (NASDAQ:ALXO) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, profitability, risk, media sentiment, earnings and institutional ownership.

In the previous week, ALX Oncology had 1 more articles in the media than Annovis Bio. MarketBeat recorded 3 mentions for ALX Oncology and 2 mentions for Annovis Bio. ALX Oncology's average media sentiment score of 1.27 beat Annovis Bio's score of -0.30 indicating that ALX Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Annovis Bio	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ALX Oncology	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Annovis Bio currently has a consensus price target of $12.00, indicating a potential upside of 966.67%. ALX Oncology has a consensus price target of $4.60, indicating a potential upside of 137.11%. Given Annovis Bio's higher probable upside, equities research analysts clearly believe Annovis Bio is more favorable than ALX Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Annovis Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
ALX Oncology	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

ALX Oncology's return on equity of -90.30% beat Annovis Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Annovis Bio	N/A	-685.98%	-258.77%
ALX Oncology	N/A	-90.30%	-67.28%

Annovis Bio has a beta of 1.24, indicating that its stock price is 24% more volatile than the broader market. Comparatively, ALX Oncology has a beta of 0.39, indicating that its stock price is 61% less volatile than the broader market.

15.8% of Annovis Bio shares are owned by institutional investors. Comparatively, 98.0% of ALX Oncology shares are owned by institutional investors. 20.8% of Annovis Bio shares are owned by insiders. Comparatively, 12.4% of ALX Oncology shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

ALX Oncology is trading at a lower price-to-earnings ratio than Annovis Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Annovis Bio	N/A	N/A	-$28.85M	-$1.79	N/A
ALX Oncology	N/A	N/A	-$101.69M	-$1.13	N/A

Summary

ALX Oncology beats Annovis Bio on 8 of the 13 factors compared between the two stocks.

How does Annovis Bio compare to Fate Therapeutics?

Annovis Bio (NYSE:ANVS) and Fate Therapeutics (NASDAQ:FATE) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, profitability, media sentiment and earnings.

Annovis Bio has a beta of 1.24, suggesting that its share price is 24% more volatile than the broader market. Comparatively, Fate Therapeutics has a beta of 2.54, suggesting that its share price is 154% more volatile than the broader market.

Annovis Bio has a net margin of 0.00% compared to Fate Therapeutics' net margin of -1,941.09%. Fate Therapeutics' return on equity of -65.08% beat Annovis Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Annovis Bio	N/A	-685.98%	-258.77%
Fate Therapeutics	-1,941.09%	-65.08%	-41.73%

15.8% of Annovis Bio shares are held by institutional investors. Comparatively, 97.5% of Fate Therapeutics shares are held by institutional investors. 20.8% of Annovis Bio shares are held by company insiders. Comparatively, 4.7% of Fate Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Annovis Bio presently has a consensus target price of $12.00, indicating a potential upside of 966.67%. Fate Therapeutics has a consensus target price of $5.90, indicating a potential upside of 155.41%. Given Annovis Bio's higher probable upside, analysts clearly believe Annovis Bio is more favorable than Fate Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Annovis Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Fate Therapeutics	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38

In the previous week, Fate Therapeutics had 2 more articles in the media than Annovis Bio. MarketBeat recorded 4 mentions for Fate Therapeutics and 2 mentions for Annovis Bio. Fate Therapeutics' average media sentiment score of 0.94 beat Annovis Bio's score of -0.30 indicating that Fate Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Annovis Bio	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Fate Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Annovis Bio has higher earnings, but lower revenue than Fate Therapeutics. Fate Therapeutics is trading at a lower price-to-earnings ratio than Annovis Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Annovis Bio	N/A	N/A	-$28.85M	-$1.79	N/A
Fate Therapeutics	$6.65M	41.62	-$136.32M	-$1.05	N/A

Summary

Fate Therapeutics beats Annovis Bio on 10 of the 15 factors compared between the two stocks.

How does Annovis Bio compare to Anika Therapeutics?

Annovis Bio (NYSE:ANVS) and Anika Therapeutics (NASDAQ:ANIK) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations.

In the previous week, Annovis Bio had 1 more articles in the media than Anika Therapeutics. MarketBeat recorded 2 mentions for Annovis Bio and 1 mentions for Anika Therapeutics. Anika Therapeutics' average media sentiment score of 0.63 beat Annovis Bio's score of -0.30 indicating that Anika Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Annovis Bio	Neutral
Anika Therapeutics	Positive

Annovis Bio has a net margin of 0.00% compared to Anika Therapeutics' net margin of -3.14%. Anika Therapeutics' return on equity of 0.20% beat Annovis Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Annovis Bio	N/A	-685.98%	-258.77%
Anika Therapeutics	-3.14%	0.20%	0.15%

Annovis Bio currently has a consensus target price of $12.00, indicating a potential upside of 966.67%. Anika Therapeutics has a consensus target price of $21.00, indicating a potential upside of 0.67%. Given Annovis Bio's higher probable upside, equities analysts clearly believe Annovis Bio is more favorable than Anika Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Annovis Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Anika Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Annovis Bio has a beta of 1.24, meaning that its stock price is 24% more volatile than the broader market. Comparatively, Anika Therapeutics has a beta of 0.2, meaning that its stock price is 80% less volatile than the broader market.

15.8% of Annovis Bio shares are owned by institutional investors. Comparatively, 91.5% of Anika Therapeutics shares are owned by institutional investors. 20.8% of Annovis Bio shares are owned by company insiders. Comparatively, 12.1% of Anika Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Anika Therapeutics has higher revenue and earnings than Annovis Bio. Anika Therapeutics is trading at a lower price-to-earnings ratio than Annovis Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Annovis Bio	N/A	N/A	-$28.85M	-$1.79	N/A
Anika Therapeutics	$120.65M	2.31	-$10.88M	-$0.27	N/A

Summary

Anika Therapeutics beats Annovis Bio on 9 of the 15 factors compared between the two stocks.

How does Annovis Bio compare to Pyxis Oncology?

Annovis Bio (NYSE:ANVS) and Pyxis Oncology (NASDAQ:PYXS) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, dividends, institutional ownership, profitability and valuation.

In the previous week, Pyxis Oncology had 22 more articles in the media than Annovis Bio. MarketBeat recorded 24 mentions for Pyxis Oncology and 2 mentions for Annovis Bio. Pyxis Oncology's average media sentiment score of 0.60 beat Annovis Bio's score of -0.30 indicating that Pyxis Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Annovis Bio	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pyxis Oncology	7 Very Positive mention(s)	2 Positive mention(s)	11 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Annovis Bio currently has a consensus target price of $12.00, indicating a potential upside of 966.67%. Pyxis Oncology has a consensus target price of $8.75, indicating a potential upside of 172.59%. Given Annovis Bio's higher probable upside, equities research analysts clearly believe Annovis Bio is more favorable than Pyxis Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Annovis Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Pyxis Oncology	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

Pyxis Oncology's return on equity of -215.23% beat Annovis Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Annovis Bio	N/A	-685.98%	-258.77%
Pyxis Oncology	N/A	-215.23%	-112.19%

15.8% of Annovis Bio shares are owned by institutional investors. Comparatively, 39.1% of Pyxis Oncology shares are owned by institutional investors. 20.8% of Annovis Bio shares are owned by insiders. Comparatively, 5.7% of Pyxis Oncology shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Annovis Bio has a beta of 1.24, suggesting that its stock price is 24% more volatile than the broader market. Comparatively, Pyxis Oncology has a beta of 1.34, suggesting that its stock price is 34% more volatile than the broader market.

Annovis Bio has higher earnings, but lower revenue than Pyxis Oncology. Pyxis Oncology is trading at a lower price-to-earnings ratio than Annovis Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Annovis Bio	N/A	N/A	-$28.85M	-$1.79	N/A
Pyxis Oncology	$11.04M	24.26	-$79.62M	-$1.41	N/A

Summary

Pyxis Oncology beats Annovis Bio on 10 of the 14 factors compared between the two stocks.

How does Annovis Bio compare to Cartesian Therapeutics?

Cartesian Therapeutics (NASDAQ:RNAC) and Annovis Bio (NYSE:ANVS) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, media sentiment, profitability, institutional ownership, risk, dividends and earnings.

Annovis Bio has a net margin of 0.00% compared to Cartesian Therapeutics' net margin of -8,550.65%. Cartesian Therapeutics' return on equity of 0.00% beat Annovis Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cartesian Therapeutics	-8,550.65%	N/A	-29.84%
Annovis Bio	N/A	-685.98%	-258.77%

Cartesian Therapeutics presently has a consensus target price of $32.60, suggesting a potential upside of 298.05%. Annovis Bio has a consensus target price of $12.00, suggesting a potential upside of 966.67%. Given Annovis Bio's higher possible upside, analysts plainly believe Annovis Bio is more favorable than Cartesian Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cartesian Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Annovis Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Cartesian Therapeutics and Cartesian Therapeutics both had 2 articles in the media. Cartesian Therapeutics' average media sentiment score of 0.93 beat Annovis Bio's score of -0.30 indicating that Cartesian Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cartesian Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Annovis Bio	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Annovis Bio has lower revenue, but higher earnings than Cartesian Therapeutics. Cartesian Therapeutics is trading at a lower price-to-earnings ratio than Annovis Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cartesian Therapeutics	$2.80M	88.48	-$130.30M	-$5.94	N/A
Annovis Bio	N/A	N/A	-$28.85M	-$1.79	N/A

Cartesian Therapeutics has a beta of 0.62, suggesting that its stock price is 38% less volatile than the broader market. Comparatively, Annovis Bio has a beta of 1.24, suggesting that its stock price is 24% more volatile than the broader market.

87.0% of Cartesian Therapeutics shares are held by institutional investors. Comparatively, 15.8% of Annovis Bio shares are held by institutional investors. 37.2% of Cartesian Therapeutics shares are held by insiders. Comparatively, 20.8% of Annovis Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Cartesian Therapeutics beats Annovis Bio on 8 of the 14 factors compared between the two stocks.

Get Annovis Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ANVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ANVS vs. The Competition

Export

Metric	Annovis Bio	Biotechnology Industry	Healthcare Sector	NYSE Exchange
Market Cap	$50.70M	$3.84B	$7.13B	$23.17B
Dividend Yield	N/A	3.63%	2.56%	3.56%
P/E Ratio	-0.63	14.25	275.24	28.71
Price / Sales	N/A	1,473.16	656.02	94.44
Price / Cash	N/A	106.68	77.04	33.82
Price / Book	1.76	15.12	10.33	4.74
Net Income	-$28.85M	-$22.86M	$3.50B	$1.07B
7 Day Performance	-18.63%	-4.34%	-3.32%	-2.00%
1 Month Performance	-37.85%	-0.02%	-0.41%	-2.69%
1 Year Performance	-54.82%	40.64%	19.21%	10.45%

Annovis Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ANVS Annovis Bio	2.284 of 5 stars	$1.13 -5.5%	$12.00 +966.7%	-52.8%	$50.70M	N/A	N/A	3	News Coverage Analyst Downgrade
ALXO ALX Oncology	2.4566 of 5 stars	$1.92 -0.8%	$4.60 +140.2%	+64.4%	$263.42M	N/A	N/A	40	Positive News
FATE Fate Therapeutics	2.5743 of 5 stars	$2.38 -0.6%	$5.90 +148.4%	+126.5%	$284.57M	$6.65M	N/A	550
ANIK Anika Therapeutics	2.6256 of 5 stars	$21.13 +1.2%	$21.00 -0.6%	+141.7%	$281.58M	$112.82M	N/A	300	News Coverage
PYXS Pyxis Oncology	3.3769 of 5 stars	$3.38 +4.3%	$7.50 +121.9%	+72.6%	$281.43M	$13.86M	N/A	60	News Coverage Positive News Analyst Forecast Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:ANVS) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Annovis Bio (ANVS) Competitors

ANVS vs. ALXO, FATE, ANIK, PYXS, and RNAC

How does Annovis Bio compare to ALX Oncology?

Summary

How does Annovis Bio compare to Fate Therapeutics?

Summary

How does Annovis Bio compare to Anika Therapeutics?

Summary

How does Annovis Bio compare to Pyxis Oncology?

Summary

How does Annovis Bio compare to Cartesian Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANVS vs. The Competition

Annovis Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Annovis Bio (ANVS) Competitors

ANVS vs. ALXO, FATE, ANIK, PYXS, and RNAC

How does Annovis Bio compare to ALX Oncology?

Does the media prefer ANVS or ALXO?

Do analysts rate ANVS or ALXO?

Is ANVS or ALXO more profitable?

Which has more risk & volatility, ANVS or ALXO?

Do insiders & institutionals have more ownership in ANVS or ALXO?

Which has stronger earnings and valuation, ANVS or ALXO?

Summary

How does Annovis Bio compare to Fate Therapeutics?

Which has more risk & volatility, ANVS or FATE?

Is ANVS or FATE more profitable?

Do institutionals and insiders have more ownership in ANVS or FATE?

Do analysts rate ANVS or FATE?

Does the media refer more to ANVS or FATE?

Which has higher valuation and earnings, ANVS or FATE?

Summary

How does Annovis Bio compare to Anika Therapeutics?

Does the media prefer ANVS or ANIK?

Is ANVS or ANIK more profitable?

Do analysts rate ANVS or ANIK?

Which has more volatility & risk, ANVS or ANIK?

Do insiders & institutionals believe in ANVS or ANIK?

Which has higher valuation & earnings, ANVS or ANIK?

Summary

How does Annovis Bio compare to Pyxis Oncology?

Does the media prefer ANVS or PYXS?

Do analysts recommend ANVS or PYXS?

Is ANVS or PYXS more profitable?

Do insiders & institutionals believe in ANVS or PYXS?

Which has more volatility and risk, ANVS or PYXS?

Which has higher valuation & earnings, ANVS or PYXS?

Summary

How does Annovis Bio compare to Cartesian Therapeutics?

Is RNAC or ANVS more profitable?

Do analysts rate RNAC or ANVS?

Does the media refer more to RNAC or ANVS?

Which has preferable earnings and valuation, RNAC or ANVS?

Which has more risk and volatility, RNAC or ANVS?

Do insiders & institutionals have more ownership in RNAC or ANVS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANVS vs. The Competition

Annovis Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools